Document Detail


One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease.
MedLine Citation:
PMID:  21360472     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The long-term antiproteinuric effects of benidipine, a calcium channel blocker (CCB), have not been evaluated in detail in hypertensive patients with chronic kidney disease (CKD).
METHODS: Benidipine (4 mg/day) was administered to previously untreated hypertensive patients with CKD, or hypertensive patients with CKD not achieving target blood pressure (BP) despite taking an angiotensin II receptor blocker (ARB). The patients were followed up for 1 year. If target BP was not achieved by 2 weeks after the start of benidipine treatment, the dosage was increased to 8 mg/day. The urinary protein to creatinine (UP/cre) ratio was evaluated before and after benidipine treatment.
RESULTS: This study evaluated 65 hypertensive patients with CKD. BP (systolic/diastolic) decreased from 154 ± 19 / 91 ± 12 mm Hg before treatment to 134 ± 16 / 78 ± 10 mm Hg at 1 year after treatment (p<0.001). The UP/cre ratio decreased significantly from 2.21 ± 2.47 g/g creatinine (g/g cre) before treatment to 1.43 ± 2.21 g/g cre after treatment (p<0.001). In both the untreated and ARB-treated groups, the BP and UP/cre ratio decreased significantly at 1 year after treatment. The percentage change in the UP/cre ratio was significantly greater in patients aged 65 years or older than in those less than 65 years (79.1% vs. 48.7%, p=0.038).
CONCLUSIONS: Benidipine treatment reduced the UP/cre ratio in hypertensive patients with CKD, and the percentage decrease of the UP/cre ratio was greater in elderly patients, suggesting that benidipine may have more potent antiproteinuric effects in elderly hypertensive patients with CKD.
Authors:
Yasuhiko Tomino; Yoshio Shimizu; Chieko Hamada; Atsushi Kurusu; Isao Ohsawa; Yusuke Suzuki; Toshinao Tsuge; Hiroaki Io; Noriyoshi Kobayashi; Yukihiko Takeda; Katsuhiko Asanuma; Yuichi Tanaka; Hitoshi Suzuki; Jun-Ichiro Nakata; Katsuhiko Takara; Satoshi Horikoshi
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of nephrology     Volume:  24     ISSN:  1724-6059     ISO Abbreviation:  J. Nephrol.     Publication Date:    2011 Nov-Dec
Date Detail:
Created Date:  2011-11-07     Completed Date:  2012-04-18     Revised Date:  2012-04-27    
Medline Journal Info:
Nlm Unique ID:  9012268     Medline TA:  J Nephrol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  756-63     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan. yasu@juntendo.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age Factors
Aged
Aged, 80 and over
Angiotensin II Type 1 Receptor Blockers / pharmacology,  therapeutic use
Blood Pressure / drug effects,  physiology
Calcium Channel Blockers / pharmacology,  therapeutic use*
Chronic Disease
Comorbidity
Creatinine / urine
Dihydropyridines / pharmacology,  therapeutic use*
Female
Follow-Up Studies
Glomerular Filtration Rate / drug effects,  physiology
Humans
Hypertension / drug therapy*,  epidemiology*,  physiopathology
Kidney Diseases / complications,  epidemiology*,  physiopathology
Longitudinal Studies
Male
Middle Aged
Proteinuria / etiology,  prevention & control*,  urine
Retrospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Calcium Channel Blockers; 0/Dihydropyridines; 105979-17-7/benidipine; 60-27-5/Creatinine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Preoperative left ventricular dysfunction predisposes to postoperative acute kidney injury and long-...
Next Document:  Implementation of exercise training programs in a hemodialysis unit: effects on physical performance...